EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial

Paula M Novelli, Emmanuel E Zervos, Amer H Zureikat, Michael J Pishvaian, Kenneth Meredith, Hassan Hatoum, Reza Nazemzadeh, Sandeep Laroia, Pashtoon Kasi, Justus Bingham, Ramtin Agah

Cancer Chemotherapy and Pharmacology · 17.08.2026 · 96 (1)

DOI: 10.1007/s00280-026-04939-0 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 17.08.2026. Verfasst von Paula M Novelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Floxuridine, Gemcitabine, Pancreatic Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: East Carolina University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Localized intra-arterial delivery of gemcitabine (IAG) may provide advantages in terms of increased tissue concentration and decreased systemic dosing. We hypothesized IAG may result in decreased systemic gemcitabine concentration and associated side effects due to intracellular delivery prior to conversion to gemcitabine’s inactive metabolite, difluorodeoxyuridine (dFdU). Here we report the results of a pharmacokinetics and pharmacodynamics sub-study within the TIGeR-PaC phase 3 clinical trial (NCT03257033).

Methods

Analyses were performed for 16 participants across 6 TIGeR-PaC study sites; 11 participants received localized IAG and 5 participants received systemic intravenous gemcitabine (IVG). Gemcitabine and dFdU assays were performed on blood samples collected immediately before, during, and after infusion. CA 19 − 9 levels were measured prior to and 2 weeks after IAG treatment. Maximum plasma drug concentration (C max ) and the area under the drug plasma concentration curve (AUC 0−t ) were compared between treatment groups. Pearson’s correlation for AUC 0−t and the percent change in CA 19 − 9 levels was calculated for the IAG group.

Results

IAG resulted in lower gemcitabine C max and AUC 0−t and higher dFdU C max and AUC 0−t compared to IVG, consistent with a more rapid conversion of gemcitabine to dFdU with IAG versus IVG. With IAG, there was a significant correlation between increased dFdU levels and a pre- to post-treatment reduction in CA 19 − 9 levels (Pearson’s r = -0.75; P = 0.034).

Conclusion

In addition to providing increased local potency, localized IAG, in which gemcitabine is rapidly converted to its inactive metabolite dFdU, may also be beneficial in decreasing gemcitabine-related systemic side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antimetabolites, AntineoplasticFloxuridineGemcitabinePancreatic NeoplasmsAgedFemaleHumansMaleMiddle AgedArea Under CurveCA-19-9 AntigenDeoxycytidineInfusions, Intra-ArterialInfusions, Intravenous

Stichwörter der Autor:innen

GemcitabineIntra-arterial chemotherapyLocally advanced pancreatic cancer (LAPC)Trans-arterial micro perfusion (TAMP)

Substanzen

2',2'-difluoro-2'-deoxyuridineAntimetabolites, AntineoplasticCA-19-9 AntigenDeoxycytidineFloxuridineGemcitabine

Autor:innen und Institutionen

  • University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Brody School of Medicine at East Carolina University, Greenville, NC, USA. zervose@ecu.edu.
  • Division of Surgical Oncology, Brody School of Medicine at East Carolina University, 600 Moye Boulevard, Greenville, 27834, NC, USA. zervose@ecu.edu.
  • Johns Hopkins University School of Medicine, Washington, DC, USA.
  • Sarasota Memorial Health Care System, Sarasota, FL, USA.
  • University of Oklahoma College of Medicine, Oklahoma City, OK, USA.

Förderung

  • East Carolina University

Zitieren

APA

Novelli, P. M., Zervos, E. E., Zureikat, A. H., Pishvaian, M. J., Meredith, K., Hatoum, H., Nazemzadeh, R., Laroia, S., Kasi, P., Bingham, J., & Agah, R. (2026). Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04939-0

Vancouver

Novelli PM, Zervos EE, Zureikat AH, Pishvaian MJ, Meredith K, Hatoum H, et al. Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04939-0

BibTeX
@article{Novelli2026,
  author = {Novelli, Paula M and Zervos, Emmanuel E and Zureikat, Amer H and Pishvaian, Michael J and Meredith, Kenneth and Hatoum, Hassan and Nazemzadeh, Reza and Laroia, Sandeep and Kasi, Pashtoon and Bingham, Justus and Agah, Ramtin},
  title = {Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04939-0}
}
Kostenlos starten →